Transparency Market Research (TMR) has published a new report titled ‘Hepatitis Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the report, the global hepatitis therapeutics market was valued at US$ 22,049.2 Mn in 2017 and is projected to expand at a CAGR of 2.3% during forecast period from 2018 to 2026. The global market is anticipated to be driven by a rise in viraemic prevalence, promising pipeline of hepatitis drugs, and supportive government initiatives encouraging patients in the adoption of hepatitis drugs. The hepatitis therapeutics market in Asia Pacific is expected to expand at a high CAGR of 3.0%, due to a high incidence of hepatitis in emerging countries such as India and China and presence of local players providing a wide range of generic hepatitis drugs in the region.
Increase in Prevalence of Viral Hepatitis Drives Market
Hepatitis is a significant public health concern across the globe. According to the World Health Organization (WHO), in 2015, approximately, 257 million people globally, or 3.5% of the population, were living with chronic hepatitis B infections. Rise in the consumption of alcohol, infections from contaminated blood sources, and increase in the number of autoimmune diseases are leading to a rise in the cases of inflammation of the liver.
Request a PDF Sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=52665
Viral hepatitis is an important source of morbidity and mortality globally. As per WHO estimates, viral hepatitis caused 1.34 million deaths in 2015, a number higher than the deaths caused by HIV. Additionally, mortality associated with viral hepatitis has increased by 22% since 2000, and the number is further expected to increase over the next few years. Hence, these factors are likely to boost demand for hepatitis therapeutics over the forecast period.
Hepatitis C Segment Dominated the Market
In terms of disease type, the global hepatitis therapeutics market has been classified into hepatitis A, hepatitis B, hepatitis C, and others. The hepatitis C segment is projected to account for a leading share of the global market during the forecast period, owing to the high prevalence of hepatitis C in developing and developed regions and availability of effective drug regimens in the market. According to the World Health Organization (WHO), approximately 71 million people were infected with chronic hepatitis C in 2017.
Hepatitis C increases the risk of liver cirrhosis and is the leading cause of liver transplant in North America and Europe. Development of advanced therapeutics by leading industry players for the effective management of disease is expected to pave the way for the hepatitis C segment over the coming years. The hepatitis B segment is projected to expand at a rapid pace over the forecast period, owing to a high mortality rate associated with hepatitis B.
Request for Analysis of COVID19 Impact on Hepatitis Therapeutics Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=52665
Multi-class Combination to be the Most Promising Segment to Invest in
Based on drug class, the global hepatitis therapeutics market has been segmented into NS5A inhibitors, nucleotide analog reverse transcriptase inhibitors, multi-class combination, nucleotide analog NS5B polymerase inhibitors, interferon & ribavirin, and others. The multi-class combination segment is projected to expand at a high CAGR during the forecast period, owing to an increase in viraemic prevalence worldwide. Industry players are focused on developing combinational therapy as it is highly effective and has fewer side-effects compared to a single regimen for the treatment of hepatitis C. Mavyret and Epclusa are some of the combinational therapeutics recently approved by the U.S. FDA.
Asia Pacific Market to Witness Strong Growth and Create High Incremental Opportunity
In terms of region, the global hepatitis therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to account for a leading share of the global market during the forecast period, owing to high awareness and access to advanced hepatitis therapeutics and high affordability of patients in the region. The hepatitis therapeutics market in Europe is expected to expand at a substantial rate between 2018 and 2026. The market in Asia Pacific is likely to expand at a rapid pace in the next few years. This is attributed to a growing patient population, increasing penetration of global manufacturers, and rising government initiatives to promote disease awareness in the region. The hepatitis therapeutics market in Latin America and Middle East & Africa is anticipated to expand at a steady pace from 2018 to 2026.
Purchase Hepatitis Therapeutics Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=52665<ype=S
Growth Strategies by Key Market Players
Key players profiled in this report are Merck & Co., Inc., Gilead Sciences, Inc., AbbVie Inc., Bristol Myers Squibb, F. Hoffmann-La Roche, Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited, and Cipla, Inc. Companies operating in the global hepatitis therapeutics market focus on R&D to develop innovative drugs used for the effective treatment of hepatitis. Market players also resort to strategic collaborations and license agreements with domestic players to expand their market foothold in developing countries.
More Trending Reports by Transparency Market Research –
Spinal Fusion Devices Market: https://www.biospace.com/article/spinal-fusion-devices-market-north-america-projected-to-lead-global-market-through-forecast-period/
Non-Invasive Prenatal Testing Market: https://www.prnewswire.com/news-releases/increased-maternal-age-of-large-populations-worldwide-generates-prodigious-sales-avenues-in-non-invasive-prenatal-testing-market-says-tmr-301285670.html
About Us
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
